TRIOCHEM PRODUCTS LIMITED

Registered Office: 4th Floor, Sambava Chambers, Sir. P. M. Road, Fort, Mumbai, Maharashtra, PIN: 400001. Telephone: 00 91 (22) 2266 3150 Fax: 00 91 (22) 2282 8181
E-mall: info@amphray.com Website: www.triochemproducts.com
Corporate Identity Number: L24249MH1972PLC015544

Ref No: TPL PP 20260649 2026; 14th August 2026

To
BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers, Dalal Street,
Fort, Mumbai: 400 001.

Security Code No. 512101 - ISIN No.: INE331E01013.

Dear Sir / Madam,

Sub: Integrated Filling (Financial) for the quarter ended 30th June 2026

Please find attached herewith the Integrated Filling (Financial) of Triochem Products Limited ("Company') for the quarter ended 30th June 2026. The same is also being made available on the website of the Company at https://www.triochemproducts.com/investor-relations/investor-relations.aspx

This disclosure is being made in compliance with the SEBI Circular No. SEBI/HO/CFD/CFD-PoD/ CIR/ P/2024/185 dated 31st December 2024 read with Circular No. 20250102-4 issued by BSE Limited dated 2nd January 2025.

You are requested to take note of the same.

Thanking you,
Yours faithfully,
For TRIOCHEM PRODUCTS LIMITED

URECA DEOLEKAR
Digitally signed by URECA DEOLEKAR
Date: 2026.08.14 17:00:13 +05'30'

Ureca Deolekar
Company Secretary & Compliance Officer
A45831
Encl.: as above

BSE LTD

ACKNOWLEDGEMENT

Acknowledgement No	:	1408202604131327	Date & Time : 14/08/2026 04:12:31 PM
Scrip Code	:	512101	
Entity Name	:	Triochem Products Limited	
Compliance Type	:	Regulation 33(3)-Integrated Finance Ind AS	
Quarter / Period	:	30/06/2026	
Mode	:	XBRL E-Filing	

Integrated Filing (Finance) Ind AS

Triochem Products Limited

General Information

Scrip code*	512101
NSE Symbol*	NOTLISTED
MSEI Symbol*	NOTLISTED
ISIN*	INE331E01013
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2026
Date of end of financial year	31-03-2027
Date of board meeting when results were approved	14-08-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	08-08-2026
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Quarterly
Reporting Quarter	First quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	
Segment Reporting	Single segment
Description of single segment	The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (Ind AS-108) "Segment Reporting" is not applicable.
Start date of board meeting	14-08-2026
Start time of board meeting	15:00:00
End date of board meeting	14-08-2026
End time of board meeting	15:45:00
Whether cash flow statement is applicable on company	
Type of cash flow statement	
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No
No. of times funds raised during the quarter	
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	Yes

Financial Results - Ind-AS

Amount in (Lakhs)

	Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2026	01-04-2026
Date of end of reporting period		30-06-2026	30-06-2026
Whether results are audited or unaudited		Unaudited	Unaudited
Nature of report standalone or consolidated		Standalone	Standalone
Part I	**Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.**		
1	**Income**		
	Revenue from operations	0.00	0.00
	Other income	16.56	16.56
	Total income	16.56	16.56
2	**Expenses**		
(a)	Cost of materials consumed	0.00	0.00
(b)	Purchases of stock-in-trade	0.00	0.00
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00
(d)	Employee benefit expense	0.75	0.75
(e)	Finance costs	0.00	0.00
(f)	Depreciation, depletion and amortisation expense	0.00	0.00
(g)	**Other Expenses**		
1	Other Expenses	3.42	3.42
	Total other expenses	3.42	3.42
	Total expenses	4.17	4.17
	Total profit before exceptional items and tax	12.39	12.39
4	Exceptional items	0.00	0.00
5	**Total profit before tax**	12.39	12.39
6	**Tax expense**		
7	Current tax	2.63	2.63
8	Deferred tax	0.28	0.28
9	**Total tax expenses**	2.91	2.91
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0.00	0.00
11	**Net Profit Loss for the period from continuing operations**	9.48	9.48
12	Profit (loss) from discontinued operations before tax	0.00	0.00
13	Tax expense of discontinued operations	0.00	0.00
14	**Net profit (loss) from discontinued operation after tax**	0.00	0.00
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0.00	0.00
16	**Total profit (loss) for period**	9.48	9.48
17	Other comprehensive income net of taxes	95.54	95.54

18	**Total Comprehensive Income for the period**	105.02	105.02
19	**Total profit or loss, attributable to**		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
20	**Total Comprehensive income for the period attributable to**		
	Comprehensive income for the period attributable to owners of parent		
	Total comprehensive income for the period attributable to owners of parent non-controlling interests		
21	**Details of equity share capital**		
	Paid-up equity share capital	24.50	24.50
	Face value of equity share capital	10.00	10.00
22	Reserves excluding revaluation reserve		
23	**Earnings per share**		
i	**Earnings per equity share for continuing operations**		
	Basic earnings (loss) per share from continuing operations	3.87	3.87
	Diluted earnings (loss) per share from continuing operations	3.87	3.87
ii	**Earnings per equity share for discontinued operations**		
	Basic earnings (loss) per share from discontinued operations	0.00	0.00
	Diluted earnings (loss) per share from discontinued operations	0.00	0.00
iii	**Earnings per equity share (for continuing and discontinued operations)**		
	Basic earnings (loss) per share from continuing and discontinued operations	3.87	3.87
	Diluted earnings (loss) per share from continuing and discontinued operations	3.87	3.87
24	Debt equity ratio		
25	Debt service coverage ratio		
26	Interest service coverage ratio		
27	Remarks for debt equity ratio		
28	Remarks for debt service coverage ratio		
29	Remarks for interest service coverage ratio		
30	Disclosure of notes on financial results	Textual Information(1)	

Text Block

Textual Information(1)	1) The above unaudited financial results of the Company for the quarter ended 30th June 2026 have been reviewed by the Audit committee of the Board and approved by the Board of Directors at its meeting held on 14.08.2026. The same have been reviewed by the Statutory Auditors who have issued an unqualified conclusion thereon. 2) The audited financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India., as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI). 3) The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (Ind AS-108) "Segment Reporting" is not applicable. 4) The assets sold had an aggregate Written Down Value (WDV) of Rs. 56.92 lakhs. The fair market value of the assets, as determined and certified by an Independent Registered Valuer, amounted to approximately Rs. 672.05 lakhs in respect of property, plant & machinery and Rs. 501.15 lakhs (net of transfer expense amounting to Rs. 8.85 lakhs) in respect of investment properties. Resultant gain of Rs. 1,116.65 lakhs has been recognised as an exceptional item in previous period result. The sale consideration was received entirely in cash. The transaction was undertaken on an arm's length basis and in the ordinary course of business, with the objective of monetising non-core assets of the Company. The proceeds from the sale are proposed to be utilised towards funding new business ventures and other strategic initiatives of the Company. 5) The figures for the preceding quarter ended 31st March 2026 as reported in these financial results, are the balancing figures between audited figures in respect of the full financial year ended 31st March 2026 and published year to date unaudited figures up to the end of third quarter of that financial year. 6) The Corresponding figures of the previous quarter/year have been regrouped, recasted and reclassified to make them comparable wherever necessary.

Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

	Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2026	01-04-2026
	Date of end of reporting period	30-06-2026	30-06-2026
	Whether results are audited or unaudited	Unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone	Standalone
1	**Segment Revenue (Income)**		
	(net sale/income from each segment should be disclosed)		
	Total Segment Revenue		
	Less: Inter segment revenue		
	Revenue from operations		
2	**Segment Result**		
	Profit (+) / Loss (-) before tax and interest from each segment		
	Total Profit before tax		
	i. Finance cost		
	ii. Other Unallocable Expenditure net off Unallocable income		
	Profit before tax		
3	**(Segment Asset - Segment Liabilities)**		
	Segment Asset		
	Total Segment Assets		
	Un-allocable Assets		
	Net Segment Assets		
4	**Segment Liabilities**		
	Segment Liabilities		
	Total Segment Liabilities		
	Un-allocable Liabilities		
	Net Segment Liabilities		
	Disclosure of notes on segments		Textual Information(1)

Text Block

Textual Information(1)	The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (Ind AS-108) "Segment Reporting" is not applicable.

Other Comprehensive Income

Amount in (Lakhs)

	Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2026	01-04-2026
	Date of end of reporting period	30-06-2026	30-06-2026
	Whether results are audited or unaudited	Unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]		
1	**Amount of items that will not be reclassified to profit and loss**		
	Total Amount of items that will not be reclassified to profit and loss		
2	Income tax relating to items that will not be reclassified to profit or loss		
3	**Amount of items that will be reclassified to profit and loss**		
1	Items that will not be reclassified to profit or Loss	136.76	136.76
2	Income tax relating to items that will not be reclassified to profit or loss	(41.22)	(41.22)
	Total Amount of items that will be reclassified to profit and loss	95.54	95.54
4	Income tax relating to items that will be reclassified to profit or loss	0.00	0.00
5	Total Other comprehensive income	95.54	95.54

Audit qualification

Sr.	Details of Audit Qualification	Type of Audit Qualification	Frequency of qualification	For Audit Qualification(s) where the impact is quantified by the auditor	For Audit Qualification(s) where the impact is not quantified by the audit		
				Management's Views	(i) Management's estimation on the impact of audit qualification	(ii) If management is unable to estimate the impact, reasons for the same	Auditor Comme on (i) c (ii) abo
No records available							

Objects for which funds have been raised and where there has been a deviation, in the following table:							
Sr.	**Original Object**	**Modified Object, if any**	**Original Allocation**	**Modified allocation, if any**	**Funds Utilised**	**Amount of Deviation/Variation for the quarter according to applicable object**	**Remarks if any**
No records available							

Format for Disclosing Outstanding Default on Loans and Debt Securities

Amount in (Lakhs)

Sr.	Particulars	Amount	Remarks
1.	**Loans / revolving facilities like cash credit from banks / financial institutions**		
A	Total amount outstanding as on date	0.00	
B	Of the total amount outstanding, amount of default as on date	0.00	
2.	**Unlisted debt securities i.e. NCDs and NCRPS**		
A	Total amount outstanding as on date	0.00	
B	Of the total amount outstanding, amount of default as on date	0.00	
3.	**Total financial indebtedness of the listed entity including short - term and long - term debt**	0.00	

General information about company	
Scrip code*	512101
NSE Symbol*	NOTLISTED
MSEI Symbol*	NOTLISTED
ISIN*	INE331E01013
Name of company	Triochem Products Limited
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-04-2026
Date of end of financial year	31-03-2027
Date of board meeting when results were approved	14-08-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	08-08-2026
Description of presentation currency	INR
Level of rounding	Lakhs
Reporting Type	Quarterly
Reporting Quarter	First quarter
Nature of report standalone or consolidated	Standalone
Whether results are audited or unaudited for the quarter ended	Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	
Segment Reporting	Single segment
Description of single segment	The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (Ind AS-108) "Segment Reporting" is not applicable.
Start date and time of board meeting	14-08-2026 15:00
End date and time of board meeting	14-08-2026 15:45
Whether cash flow statement is applicable on company	
Type of cash flow statement	
Declaration of unmodified opinion or statement on impact of audit qualification	Not applicable
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?	No
No. of times funds raised during the quarter	
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	Yes

	Financial Results – Ind-AS		
	Particulars	3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
	Date of start of reporting period	01-04-2026	01-04-2026
	Date of end of reporting period	30-06-2026	30-06-2026
	Whether results are audited or unaudited	Unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone	Standalone
Part I	**Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.**		
1	**Income**		
	Revenue from operations	0	0
	Other income	16.56	16.56
	Total income	**16.56**	**16.56**
2	**Expenses**		
(a)	Cost of materials consumed	0	0
(b)	Purchases of stock-in-trade	0	0
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0	0
(d)	Employee benefit expense	0.75	0.75
(e)	Finance costs	0	0
(f)	Depreciation, depletion and amortisation expense	0	0
(g)	**Other Expenses**		
1	Other Expenses	3.42	3.42
	Total other expenses	**3.42**	**3.42**
	Total expenses	**4.17**	**4.17**
3	**Total profit before exceptional items and tax**	**12.39**	**12.39**
4	Exceptional items	0	0
5	**Total profit before tax**	**12.39**	**12.39**
6	**Tax expense**		
7	Current tax	2.63	2.63
8	Deferred tax	0.28	0.28
9	**Total tax expenses**	**2.91**	**2.91**
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	**Net Profit Loss for the period from continuing operations**	**9.48**	**9.48**
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	**Net profit (loss) from discontinued operation after tax**	**0**	**0**
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	**Total profit (loss) for period**	**9.48**	**9.48**
17	Other comprehensive income net of taxes	95.54	95.54
18	**Total Comprehensive Income for the period**	**105.02**	**105.02**
19	**Total profit or loss, attributable to**		
	Profit or loss, attributable to owners of parent		
	Total profit or loss, attributable to non-controlling interests		
20	**Total Comprehensive income for the period attributable to**		
	Comprehensive income for the period attributable to owners of parent		
	Total comprehensive income for the period attributable to owners of parent non-controlling interests		
21	**Details of equity share capital**		

	Paid-up equity share capital	24.5	24.5	
	Face value of equity share capital	10	10	
22	Reserves excluding revaluation reserve			
23	**Earnings per share**			
i	**Earnings per equity share for continuing operations**			
	Basic earnings (loss) per share from continuing operations	3.87	3.87	
	Diluted earnings (loss) per share from continuing operations	3.87	3.87	
ii	**Earnings per equity share for discontinued operations**			
	Basic earnings (loss) per share from discontinued operations	0	0	
	Diluted earnings (loss) per share from discontinued operations	0	0	
iii	**Earnings per equity share (for continuing and discontinued operations)**			
	Basic earnings (loss) per share from continuing and discontinued operations	3.87	3.87	
	Diluted earnings (loss) per share from continuing and discontinued operations	3.87	3.87	
24	Debt equity ratio			Textual Information(1)
25	Debt service coverage ratio			Textual Information(2)
26	Interest service coverage ratio			Textual Information(3)
27	**Disclosure of notes on financial results**	**Textual Information(4)**		

Text Block	
Textual Information(4)	1) The above unaudited financial results of the Company for the quarter ended 30th June 2026 have been reviewed by the Audit committee of the Board and approved by the Board of Directors at its meeting held on 14.08.2026. The same have been reviewed by the Statutory Auditors who have issued an unqualified conclusion thereon. 2) The audited financial results have been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India., as applicable and guidelines issued by the Securities and Exchange Board of India (SEBI). 3) The Company operates in single segment only, i.e. chemical and pharmaceuticals; therefore, disclosure requirement of Indian Accounting Standard (Ind AS-108) "Segment Reporting" is not applicable. 4) The assets sold had an aggregate Written Down Value (WDV) of Rs. 56.92 lakhs. The fair market value of the assets, as determined and certified by an Independent Registered Valuer, amounted to approximately Rs. 672.05 lakhs in respect of property, plant & machinery and Rs. 501.15 lakhs (net of transfer expense amounting to Rs. 8.85 lakhs) in respect of investment properties. Resultant gain of Rs. 1,116.65 lakhs has been recognised as an exceptional item in previous period result. The sale consideration was received entirely in cash. The transaction was undertaken on an arm's length basis and in the ordinary course of business, with the objective of monetising non-core assets of the Company. The proceeds from the sale are proposed to be utilised towards funding new business ventures and other strategic initiatives of the Company. 5) The figures for the preceding quarter ended 31st March 2026 as reported in these financial results, are the balancing figures between audited figures in respect of the full financial year ended 31st March 2026 and published year to date unaudited figures up to the end of third quarter of that financial year. 6) The Corresponding figures of the previous quarter/year have been regrouped, recasted and reclassified to make them comparable wherever necessary.

	Other Comprehensive Income		
	Date of start of reporting period	01-04-2026	01-04-2026
	Date of end of reporting period	30-06-2026	30-06-2026
	Whether results are audited or unaudited	Unaudited	Unaudited
	Nature of report standalone or consolidated	Standalone	Standalone
	Other comprehensive income [Abstract]		
1	Amount of items that will not be reclassified to profit and loss		
	Total Amount of items that will not be reclassified to profit and loss		
2	Income tax relating to items that will not be reclassified to profit or loss		
3	Amount of items that will be reclassified to profit and loss		
1	Items that will not be reclassified to profit or Loss	136.76	136.76
2	Income tax relating to items that will not be reclassified to profit or loss	-41.22	-41.22
	Total Amount of items that will be reclassified to profit and loss	95.54	95.54
4	Income tax relating to items that will be reclassified to profit or loss	0.00	0.00
5	Total Other comprehensive income	95.54	95.54

Format for Disclosing Outstanding Default on Loans and Debt Securities			
Sr. No.	Particulars	Amount	Remarks
1.	Loans / revolving facilities like cash credit from banks / financial institutions		
A	Total amount outstanding as on date	0	
B	Of the total amount outstanding, amount of default as on date	0	
2.	Unlisted debt securities i.e. NCDs and NCRPS		
A	Total amount outstanding as on date	0	
B	Of the total amount outstanding, amount of default as on date	0	
3.	Total financial indebtedness of the listed entity including short-term and long-term debt	0	